目的:人绒毛膜促性腺激素(human chorionic gonadotropin,hCG)是近30年发展免疫避孕疫苗的首选抗原。以hCG的全β亚基为免疫原和以C末端109~145的37个氨基酸肽段为免疫原研制的避孕疫苗,通过了临床前的毒性与安全性试验,并完成了第一期、第二期临床试验。本文介绍hCG避孕疫苗在国际上的临床研究以及我国临床前预初试验的概况。 OBJECTIVE: Human chorionic gonadotropin (hCG) is the preferred antigen for developing an immunocontraceptive vaccine in the past 30 years. The contraceptive vaccine developed by using the full β subunit of hCG as the immunogen and the 37 amino acid peptide fragment of 109 to 145 at the C terminal as the immunogen passed the preclinical toxicity and safety test and completed the first phase, Phase II clinical trial. This article describes the hCG contraceptive vaccine in international clinical studies and clinical preclinical trials in China.